Clinical Trial Update: A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Pfizer's PF-07820435 study in advanced solid tumors, including non-small-cell lung cancer and other indications, has been terminated at Phase 1; the update cove…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Carcinoma
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Urothelial Carcinoma

Drugs mentioned

• PF-07820435

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Status: TERMINATED